‹ Screener

SOS Ltd

SOS · Security & Commodity Brokers, Dealers, Exchanges & Services · EDGAR filings ↗

Reference price $1.64 — last insider sale, 2026-01-28 (estimated from the dated SEC Form 4 price — not a live quote)

Grade

F38

Distressed China-based commodities-trading/crypto micro-cap with material control weaknesses and essentially no cash runway.

Strengths

Risks

Notable findings

Key metrics

Gross margin
1.5%
Operating margin
-63.9%
Net margin
-63.1%
Return on assets
-20.9%
Revenue growth (QoQ)
-33.3%
Current ratio
11.0×
Free cash flow
-$247M
EBITDA
-$90M
Cash & investments
$3M
Cash runway
0q
Stock comp / revenue
4.6%

Insider transactions · last 18 months

DateInsiderTypeSharesPrice
2026-01-28Brown Douglas LewisSell13K$1.64
2026-01-28Brown Douglas LewisSell13K$1.64

All non-derivative Form 4 activity (SEC), newest first.

Clinical trials

TrialTitlePhaseStatusPrimary completion
NCT05764499 ↗Physiotherapy Scoliosis Specific Exercise Improves Truncal Shift in Idiopathic Scoliosis
Scoliosis, Apical Deviation
Completed2021-12-31
NCT03462264 ↗Strategies to Improve Home Exercise Compliance in Patients With Scoliosis: the Use of a Mobile Application
Scoliosis
NAUnknown2018-12-21

Source: ClinicalTrials.gov (U.S. NIH) · active studies first.

Recent filings

FormFiledPeriodAccession
20-F2026-05-152025-12-310001213900-26-057725 ↗
20-F2025-05-152024-12-310001213900-25-044183 ↗
20-F2024-05-152023-12-310001213900-24-043545 ↗
20-F2023-05-182022-12-310001213900-23-041000 ↗
20-F2022-05-022021-12-310001213900-22-023020 ↗
20-F2021-05-052020-12-310001213900-21-024630 ↗
20-F2020-06-152019-12-310001564590-20-029350 ↗
20-F2019-11-132018-12-310000950123-19-010836 ↗
20-F2018-04-302017-12-310001564590-18-009696 ↗